Brolucizumab Use in Treatment Resistant Neovascular Age Related Macular Degeneration (nAMD)

被引：0
|
作者：
Shortell, Justin [1 ]
Hill, Christine [2 ]
Thomas, Claire [3 ]
Peck, Travis [1 ]
Melamud, Alexander [1 ]
机构：
[1] MedStar Georgetown Univ Hosp, Ophthalmol, Washington, DC USA
[2] Med Univ South Carolina, Ophthalmol, Charleston, SC USA
[3] Univ Virginia, Charlottesville, VA USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2023年 / 64卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] INTRAOCULAR INFLAMMATION FOLLOWING INTRAVITREAL FARICIMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
    Punit, Ankita Abhinandan
    Hasan, Hani
    Da Costa, Joanna
    EYE, 2024, 38 : 173 - 173
  • [42] Ranibizumab in neovascular age related macular degeneration (nAMD)-5-Year audit data
    Prakash, Priya
    Dorairaj, Paul
    Chittajulu, Nivedita
    Butt, Adil
    Ghaloo, Anila
    Cheema, Ravinder Singh
    EYE, 2017, 31 : S7 - S8
  • [43] Clinical Outcomes of Intravitreal Brolucizumab Injection for Refractory Neovascular Age-related Macular Degeneration
    Lee, Jun Young
    Park, No Hae
    Kwon, Han Jo
    Park, Sung Who
    Byon, Ik Soo
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2024, 65 (09): : 596 - 604
  • [44] Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
    Sarkar, Aira
    Junnuthula, Vijayabhaskarreddy
    Dyawanapelly, Sathish
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [45] Baseline characteristics associated with the first year treatment interval of intravitreal faricimab in neovascular age related macular degeneration (nAMD)
    Rafijah, Neala
    Shah, Parth Arvind
    Tang, Yannan
    Willis, Jeffrey
    Kotecha, Aachal
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [46] A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
    Johnston, Robert L.
    Carius, Hans-Joachim
    Skelly, Adrian
    Ferreira, Alberto
    Milnes, Fran
    Mitchell, Paul
    ADVANCES IN THERAPY, 2017, 34 (03) : 703 - 712
  • [47] First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
    Abdin, Alaa Din
    Aljundi, Wissam
    El Jawhari, Khalil
    Suffo, Shady
    Weinstein, Isabel
    Seitz, Berthold
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [48] Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis
    Siddiqui, Zasim Azhar
    Dhumal, Trupti
    Patel, Jay
    LeMasters, Traci
    Almony, Arghavan
    Kamal, Khalid M.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (12): : 1350 - 1364
  • [49] Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab
    Rossi, Settimio
    Gesualdo, Carlo
    Marano, Ernesto
    Perrotta, Raffaele
    Trotta, Maria Consiglia
    Del Giudice, Antonio
    Simonelli, Francesca
    FRONTIERS IN MEDICINE, 2025, 11
  • [50] Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age-related macular degeneration
    Zakaria, Nadia
    Guerard, Nicolas
    Emanuelli, Andres
    Dugel, Pravin
    Watts, Jen
    Liew, Melissa
    Gekkieva, Margarita
    Hinder, Markus
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2022, 10 (02):
12345